The meeting announced below concerns Economic Studies of Immunization Policies and Practices, Funding Opportunity Announcement (FOA) IP15-001 and US Platform to Measure Influenza Vaccine Start Printed Page 15618Effectiveness against Laboratory-Confirmed Influenza-Associated Hospitalizations, FOA IP15-002, initial review.
In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting:
Time And Date: 10:00 a.m.-4:00 p.m., April 15, 2015 (Closed).
Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463.
Matters For Discussion: The meeting will include the initial review, discussion, and evaluation of applications received in response to “Economic Studies of Immunization Policies and Practices”, FOA IP15-001 and “US Platform to Measure Influenza Vaccine Effectiveness against Laboratory-confirmed Influenza-associated Hospitalizations”, FOA IP15-002.
Contact Person For More Information: Gregory Anderson, M.S., M.P.H., Scientific Review Officer, CDC, 1600 Clifton Road NE., Mailstop E60, Atlanta, Georgia 30333, Telephone: (404) 718-8833.
The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.
[FR Doc. 2015-06651 Filed 3-23-15; 8:45 am]
BILLING CODE 4163-18-P